Regeneron Q3 Surge: Dupixent Soars 35%, Total Revenue Up 36%

What happened

Regeneron reported strong Q3 2026 results, with Dupixent global net sales jumping 35% year over year to $6.5 billion, driving total revenue up 36% to $5.1 billion. This underscores the robustness of the Sanofi-partnered immunology franchise, which serves as a critical earnings backstop during the ongoing Eylea transition. The news aligns with the bull scenario in the DeepValue master report, where Dupixent profit-share growth above 20% supports operating income expansion. However, the article does not provide updates on the key catalysts: Eylea HD demand stabilization and the expected Q2 2026 pre-filled syringe approval. Investors should treat this as positive confirmation of one pillar while awaiting clarity on the other.

Implication

For long-term investors, the Q3 beat reinforces that Regeneron's revenue is becoming less dependent on the volatile retina franchise, potentially supporting a higher valuation floor. However, until management confirms Eylea HD demand stabilization and the PFS approval, the stock may remain range-bound, with upside contingent on those catalysts. If retina trends disappoint, even robust Dupixent growth may not prevent a de-rating, given the market's focus on the Eylea transition.

Thesis delta

The new data indicates Dupixent growth is accelerating, strengthening the bull case's assumption of a reliable earnings backstop. This slightly increases confidence in the base and bull scenarios but does not change the central thesis that Eylea HD stabilization and PFS approval are the key near-term catalysts. The potential buy rating remains intact, with conviction unchanged at 3.5, though the risk/reward now skews slightly more favorable.